Biopharma Stock Alert for CombinatoRx Inc. Issued by Beacon Equity
04 Março 2010 - 12:50AM
BeaconEquity.com announces an investment report featuring
pharmaceutical company CombinatoRx Inc. (Nasdaq:CRXX). The
report includes financial, comparative and investment analysis, and
pertinent industry information you need to know to make an educated
investment decision.
It is available at: http://www.beaconequity.com/i/CRXX
Get our alerts BEFORE the rest of the market. Follow us on
Twitter: http://twitter.com/BeaconEquity
CombinatoRx Inc. (CRXX) is a biopharmaceutical company focused
on developing synergistic combination pharmaceuticals. The Company
has devoted substantially all of its resources to the development
of its drug discovery technology and the research and development
of its drug candidates, including conducting pre-clinical and
clinical trials and seeking intellectual property protection for
its technology and product candidates. It has been advancing a
portfolio of four product candidates, Synavive, CRx-102, CRx-401,
CRx-191 and CRx-197, through clinical research and development, and
has a number of product candidates that have either completed Phase
IIa clinical trials or are in pre-clinical
development.
Message Board Search for
CRXX: http://www.boardcentral.com/boards/CRXX
In the report, the analyst notes:
"As of September 30, 2009, CRXX had cash, cash equivalents,
restricted cash and short-term investments of $22.2 million
compared to $30.6 million on June 30, 2009, and $43.7 million on
December 31, 2008. This decrease from June 30, 2009, is primarily
due to $2.6 million in restructuring costs and $1.8 million in
professional fees associated with the Company's ongoing strategic
realignment and proposed merger with Neuromed.
"CRXX earlier this week announced that the U.S. Food and Drug
Administration (FDA) has approved the New Drug Application (NDA)
for Exalgo(TM) (hydromorphone HCl) extended-release tablets, for
the management of moderate to severe pain in opioid tolerant
patients requiring continuous, around-the-clock opioid analgesia
for an extended period of time."
To read the entire report visit:
http://www.beaconequity.com/i/CRXX
See what investors are saying about CRXX at penny stock
forum
BeaconEquity.com is one of the industry's largest small-cap
report providers. Beacon strives to provide a balanced view of many
promising small-cap companies that would otherwise fall under the
radar of the typical Wall Street investor. We provide investors
with an excellent first step in their research and due diligence by
providing daily trading ideas, and consolidating the public
information available on them. For more information on Beacon
Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON
THIS REPORT. We are not registered as a securities broker-dealer or
an investment adviser either with the U.S. Securities and Exchange
Commission (the "SEC") or with any state securities regulatory
authority. We are neither licensed nor qualified to provide
investment advice. Beacon Equity Research nor its affiliates have a
beneficial interest in the mentioned company; nor have they
received compensation of any kind for any of the companies listed
in this communication. The information contained in our report is
not an offer to buy or sell securities. We distribute
opinions, comments and information free of charge exclusively to
individuals who wish to receive them.
CONTACT: Beacon Equity Research
Jeff Bishop
(469)-252-3505
press@beaconequity.com
Combinatorx (NASDAQ:CRXX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Combinatorx (NASDAQ:CRXX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024